Evidence map›Paper›PMID 28862952›Full record

ArticleJournal of the American Heart Association2017

Sex-Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation.

Ghanshyam Palamaner Subash Shantha, Amgad Mentias, Chakradhari Inampudi, Anita A Kumar, Kongkiat Chaikriangkrai, Viraj Bhise, Abhishek Deshmukh, Nileshkumar Patel, Samir Pancholy, Phillip A Horwitz and 5 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Ghanshyam Palamaner Subash ShanthaDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Amgad MentiasDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Chakradhari InampudiDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Anita A KumarHealth, Behavior and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
Kongkiat ChaikriangkraiDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Viraj BhiseDepartment of Management, Policy and Community Health, School of Public Health, University of Texas Health Science Center at Houston, TX.
Abhishek DeshmukhDepartment of Electrophysiology, Mayo Clinic, Rochester, MN.
Nileshkumar PatelDepartment of Cardiology, Jackson Memorial Hospital, University of Miami, FL.
Samir PancholyDepartment of Cardiovascular Medicine, The Wright Center for Graduate Medical Education, Scranton, PA.
Phillip A HorwitzDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Steven MickelsenDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Prashant D BhaveCardiology Division/Electrophysiology Section, Wake Forest Baptist Hospital, Winston-Salem, NC.
Michael GiudiciDivision of Cardiovascular Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Hakan OralDepartment of Electrophysiology, University of Michigan, Ann Arbor, MI.
Mary S Vaughan SarrazinDepartment of Internal Medicine, Roy and Lucille J. Carver College of Medicine, University of Iowa, Iowa City, IA mary-vaughan-sarrazin@uiowa.edu.
University of Iowa Hospitals and Clinics · USAtrium Health Wake Forest Baptist · USJohns Hopkins University · USMichigan Medicine · USThe University of Texas Health Science Center · USThe Wright Center for Graduate Medical Education · USUniversity of Iowa · USUniversity of Miami · USWinnMed · US

Funding

AHRQ HHS R01 HS023104
6 · The paper itself

Abstract

backgroundSex-specific effectiveness of rivaroxaban (RIVA), dabigatran (DABI), and warfarin in reducing myocardial infarction (MI), heart failure (HF), and all-cause mortality among patients with atrial fibrillation are not known. We assessed sex-specific associations of RIVA, DABI, or warfarin use with the risk of MI, HF, and all-cause mortality among patients with atrial fibrillation. METHODS AND

resultsMedicare beneficiaries (men: 65 734 [44.8%], women: 81 135 [55.2%]) with atrial fibrillation who initiated oral anticoagulants formed the study cohort. Inpatient admissions for MI, HF, and all-cause mortality were compared between the 3 drugs separately for men and women using 3-way propensity-matched samples. In men, RIVA use was associated with a reduced risk of MI admissions compared with warfarin use (hazard ratio [95% confidence interval (CI): 0.59 [0.38-0.91]), with a trend towards reduced risk compared with DABI use (0.67 [0.44-1.01]). In women, there were no significant differences in the risk of MI admissions across all 3 anticoagulants. In both sexes, RIVA use and DABI use were associated with reduced risk of HF admissions (men: RIVA; 0.75 [0.63-0.89], DABI; 0.81 [0.69-0.96]) (women: RIVA; 0.64 [0.56-0.74], DABI; 0.73 [0.63-0.83]) and all-cause mortality (men: RIVA; 0.66 [0.53-0.81], DABI; 0.75 [0.61-0.93]) (women: RIVA; 0.76 [0.63-0.91], DABI; 0.77 [0.64-0.93]) compared with warfarin use.

conclusionsRIVA use and DABI use when compared with warfarin use was associated with a reduced risk of HF admissions and all-cause mortality in both sexes. However, reduced risk of MI admissions noted with RIVA use appears to be limited to men.

Indexed as

Administration, OralAdministrative Claims, HealthcareAgedAged, 80 and overAnticoagulantsAtrial FibrillationCause of DeathChi-Square DistributionDabigatranDatabases, FactualFemaleHeart FailureHumansKaplan-Meier EstimateMaleMedicareAnticoagulantsDabigatranRivaroxabanWarfarinatrial fibrillationheart failuremortalitymyocardial infarctionsex

Identifiers

PMID28862952
PMCPMC5586467
OpenAlexW2749861182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.